• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Cognitive Disorders - Pipeline Review, H2 2012 Product Image

Cognitive Disorders - Pipeline Review, H2 2012

  • ID: 2366426
  • December 2012
  • 286 pages
  • Global Markets Direct

Cognitive Disorders – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Cognitive Disorders - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Cognitive Disorders, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cognitive Disorders. Cognitive Disorders - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Cognitive Disorders.
- A review of the Cognitive Disorders products under development by companies and universities/research READ MORE >

Note: Product cover images may vary from those shown

2
List of Tables 7
List of Figures 9
Introduction 10
REPORT COVERAGE 10
Cognitive Disorders Overview 11
Therapeutics Development 12
An Overview of Pipeline Products for Cognitive Disorders 12
Cognitive Disorders Therapeutics under Development by Companies 14
Cognitive Disorders Therapeutics under Investigation by Universities/Institutes 20
Late Stage Products 24
Comparative Analysis 24
Mid Clinical Stage Products 25
Comparative Analysis 25
Early Clinical Stage Products 26
Comparative Analysis 26
Discovery and Pre-Clinical Stage Products 27
Comparative Analysis 27
Cognitive Disorders Therapeutics – Products under Development by Companies 28
Cognitive Disorders Therapeutics – Products under Investigation by Universities/Institutes 34
Companies Involved in Cognitive Disorders Therapeutics Development 37
F. Hoffmann-La Roche Ltd. 37
Abbott Laboratories 38
Amgen Inc. 39
Eli Lilly and Company 40
GlaxoSmithKline plc 41
Takeda Pharmaceutical Company Limited 42
Albany Molecular Research, Inc. 43
Avineuro Pharmaceuticals, Inc. 44
Sylentis 45
Aphios Corporation 46
Astellas Pharma Inc. 47
Kowa Company, Ltd. 48
Teva Pharmaceutical Industries Limited 49
Shire Plc 50
Washington University School of Medicine 51
Evotec Aktiengesellschaft 52
Neuralstem, Inc. 53
American Biogenetic Sciences, Inc. 54
Ligand Pharmaceuticals Incorporated 55
Neuren Pharmaceuticals Limited 56
Ore Pharmaceuticals Inc 57
ACADIA Pharmaceuticals Inc. 58
WhanIn Pharmaceutical Co., Ltd. 59
SYGNIS Pharma AG 60
Biotie Therapies Corp. 61
Allon Therapeutics Inc. 62
Suven Life Sciences Ltd. 63
Proximagen Neuroscience plc. 64
Oryzon 65
M et P Pharma AG 66
Bio-Link 67
Celon Pharma Sp. z o.o. 68
BIOALVO S.A. 69
PsychoGenics, Inc. 70
SeneXta Therapeutics SA 71
Intellect Neurosciences, Inc. 72
Dart NeuroScience LLC 73
Omeros Corporation 74
Adeona Pharmaceuticals, Inc. 75
Intra-Cellular Therapies, Inc. 76
Sparsha Pharma International Pvt. Ltd. 77
Tautatis Incorporated 78
Galenea Corp. 79
Stelic Institute & Co. 80
Cenomed, Inc. 81
Gaia BioPharma Limited 82
Heptares Therapeutics Ltd. 83
Envoy Therapeutics, Inc. 84
BIOPROJET SCR 85
Naurex, Inc. 86
Cognitive Disorders – Therapeutics Assessment 87
Assessment by Monotherapy Products 87
Assessment by Route of Administration 88
Assessment by Molecule Type 90
Drug Profiles 92
SB-742457 - Drug Profile 92
GSK-239512 - Drug Profile 94
MEM-68626 - Drug Profile 96
irdabisant hydrochloride - Drug Profile 97
AMG-747 - Drug Profile 98
ASP-0777 - Drug Profile 99
AVN-211 - Drug Profile 100
AM-831 - Drug Profile 101
BLV-0703 - Drug Profile 102
OMS-824 - Drug Profile 103
pregnenolone - Drug Profile 104
GAI-122 - Drug Profile 105
SYN-120 - Drug Profile 107
IRAP Inhibitors - Drug Profile 108
Kibra - Drug Profile 109
Histamine H3 Receptor Antagonist - Drug Profile 110
estriol - Drug Profile 111
G Family Inhibitor For Dementia - Drug Profile 113
5-HT6 Program - Drug Profile 114
NSD-761 - Drug Profile 115
ABT-560 - Drug Profile 116
eltoprazine - Drug Profile 117
BVT-74316 - Drug Profile 118
NNZ-2591 - Drug Profile 120
AVN-457 - Drug Profile 122
AVN-492 - Drug Profile 123
AVN-458 - Drug Profile 124
BF2-649 - Drug Profile 125
levothyroxine sodium - Drug Profile 126
armodafinil - Drug Profile 127
valacyclovir hydrochloride - Drug Profile 128
bupropion hydrochloride - Drug Profile 129
donepezil hydrochloride - Drug Profile 130
ABT-126 - Drug Profile 131
nimodipine - Drug Profile 133
donepezil hydrochloride - Drug Profile 134
TTT-3002 - Drug Profile 135
SUVN-502 - Drug Profile 136
RG-1662 - Drug Profile 138
dexmedetomidine hydrochloride - Drug Profile 139
ABT-288 - Drug Profile 140
ITI-002 - Drug Profile 141
SNX-001 - Drug Profile 142
lisdexamfetamine dimesylate - Drug Profile 144
selegiline hydrochloride - Drug Profile 147
Memantine - Drug Profile 148
donepezil hydrochloride - Drug Profile 149
pioglitazone hydrochloride - Drug Profile 150
tiprolisant - Drug Profile 151
epoetin alfa - Drug Profile 153
memantine hydrochloride - Drug Profile 155
donepezil hydrochloride - Drug Profile 156
citicoline sodium - Drug Profile 157
haloperidol - Drug Profile 158
midazolam hydrochloride - Drug Profile 159
pioglitazone hydrochloride - Drug Profile 160
tolcapone - Drug Profile 161
tolcapone - Drug Profile 162
ziprasidone hydrochloride - Drug Profile 163
ND-0801 - Drug Profile 164
cycloserine - Drug Profile 165
K-828-AB - Drug Profile 166
5-HT6 Antagonist Program - Drug Profile 167
NSI-189 - Drug Profile 169
Drug For Dementia - Drug Profile 171
EVT-501 - Drug Profile 172
D1 Agonist Program - Drug Profile 173
etanercept - Drug Profile 174
PD and AD Program - Drug Profile 175
HT-0712 - Drug Profile 176
APH-0703 - Drug Profile 178
dronabinol - Drug Profile 179
alemtuzumab - Drug Profile 180
troxerutin - Drug Profile 181
Alpha-7 Programme - Drug Profile 183
cycloserine - Drug Profile 184
GPR12 Antagonist - Drug Profile 185
davunetide - Drug Profile 186
ladostigil tartrate - Drug Profile 187
Anti-TNF Alpha Therapy - Drug Profile 189
NMDAR modulators - Drug Profile 190
M1 Receptor Agonist - Drug Profile 191
rivastigmine - Drug Profile 192
Midazolam - Drug Profile 193
methylphenidate hydrochloride - Drug Profile 194
edaravone - Drug Profile 196
SUVN-501 - Drug Profile 197
Dihydrexidine - Drug Profile 198
SUVN-507 - Drug Profile 199
SUVN-901 - Drug Profile 200
SUVN-976 - Drug Profile 201
Histamine-3 Antagonist - Drug Profile 202
Drug Acting On Nicotinic Acetylcholine Receptor Alpha-4 Beta-2 For Neuro Degenerative Diseases - Drug Profile 203
5-HT4 agonist and Partial agonist - Drug Profile 204
insulin aspart recombinant - Drug Profile 205
AMG-579 - Drug Profile 206
MGluR5 PAM - Drug Profile 207
Program 2 For Cognitive Impairment - Drug Profile 208
Drug Targeting GPR83 - Drug Profile 209
lisdexamfetamine dimesylate - Drug Profile 210
Drug Targeting GPR151 - Drug Profile 211
OG-45 - Drug Profile 212
OG-49 - Drug Profile 213
Drug Targeting MAS1 - Drug Profile 214
Donepezil - Drug Profile 215
sGC-1061 - Drug Profile 216
ABS-205 - Drug Profile 217
SEL-141 Program - Drug Profile 218
WIB-1001C - Drug Profile 219
Gugulipid - Drug Profile 220
Drug For Cognitive Impairment - Drug Profile 221
CPL-204-015 - Drug Profile 222
dalfampridine SR - Drug Profile 223
amphetamine XR - Drug Profile 224
etanercept - Drug Profile 225
GSK-2981710 - Drug Profile 226
Monoclonal Antibodies Targeting Tau Protein - Drug Profile 227
CB-2433 - Drug Profile 228
Tetrahydrocarbazole Derivatives - Drug Profile 229
Drug Targeting NAT / H3 - Drug Profile 230
5HTT/5HT2C Modulator - Drug Profile 231
ITI-214 - Drug Profile 232
T01-OX2 - Drug Profile 233
VCP Inhibitor - Drug Profile 234
HT-1067 - Drug Profile 235
mifepristone - Drug Profile 236
Drug Targeting nAChR Alpha 4 Beta 2 - Drug Profile 237
meldonium - Drug Profile 238
Cognitive Disorders Therapeutics – Drug Profile Updates 239
Cognitive Disorders Therapeutics – Discontinued Products 260
Cognitive Disorders Therapeutics - Dormant Products 262
Cognitive Disorders – Product Development Milestones 269
Featured News & Press Releases 269
Appendix 276
Methodology 276
Coverage 276
Secondary Research 276
Primary Research 276
Expert Panel Validation 276
Contact Us 277
Disclaimer 277

List of Tables
Number of Products Under Development for Cognitive Disorders, H2 2012 21
Products under Development for Cognitive Disorders – Comparative Analysis, H2 2012 22
Number of Products under Development by Companies, H2 2012 24
Number of Products under Development by Companies, H2 2012 (Contd..1) 25
Number of Products under Development by Companies, H2 2012 (Contd..2) 26
Number of Products under Development by Companies, H2 2012 (Contd..3) 27
Number of Products under Development by Companies, H2 2012 (Contd..4) 28
Number of Products under Investigation by Universities/Institutes, H2 2012 30
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 31
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..2) 32
Comparative Analysis by Late Stage Development, H2 2012 33
Comparative Analysis by Mid Clinical Stage Development, H2 2012 34
Comparative Analysis by Early Clinical Stage Development, H2 2012 35
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 36
Products under Development by Companies, H2 2012 37
Products under Development by Companies, H2 2012 (Contd..1) 38
Products under Development by Companies, H2 2012 (Contd..2) 39
Products under Development by Companies, H2 2012 (Contd..3) 40
Products under Development by Companies, H2 2012 (Contd..4) 41
Products under Development by Companies, H2 2012 (Contd..5) 42
Products under Investigation by Universities/Institutes, H2 2012 43
Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 44
Products under Investigation by Universities/Institutes, H2 2012 (Contd..2) 45
F. Hoffmann-La Roche Ltd., H2 2012 46
Abbott Laboratories, H2 2012 47
Amgen Inc., H2 2012 48
Eli Lilly and Company, H2 2012 49
GlaxoSmithKline plc, H2 2012 50
Takeda Pharmaceutical Company Limited, H2 2012 51
Albany Molecular Research, Inc., H2 2012 52
Avineuro Pharmaceuticals, Inc., H2 2012 53
Sylentis, H2 2012 54
Aphios Corporation, H2 2012 55
Astellas Pharma Inc., H2 2012 56
Kowa Company, Ltd., H2 2012 57
Teva Pharmaceutical Industries Limited, H2 2012 58
Shire Plc, H2 2012 59
Washington University School of Medicine, H2 2012 60
Evotec Aktiengesellschaft, H2 2012 61
Neuralstem, Inc., H2 2012 62
American Biogenetic Sciences, Inc., H2 2012 63
Ligand Pharmaceuticals Incorporated, H2 2012 64
Neuren Pharmaceuticals Limited, H2 2012 65
Ore Pharmaceuticals Inc, H2 2012 66
ACADIA Pharmaceuticals Inc., H2 2012 67
WhanIn Pharmaceutical Co., Ltd., H2 2012 68
SYGNIS Pharma AG, H2 2012 69
Biotie Therapies Corp., H2 2012 70
Allon Therapeutics Inc., H2 2012 71
Suven Life Sciences Ltd., H2 2012 72
Proximagen Neuroscience plc., H2 2012 73
Oryzon, H2 2012 74
M et P Pharma AG, H2 2012 75
Bio-Link, H2 2012 76
Celon Pharma Sp. z o.o., H2 2012 77
BIOALVO S.A., H2 2012 78
PsychoGenics, Inc., H2 2012 79
SeneXta Therapeutics SA, H2 2012 80
Intellect Neurosciences, Inc., H2 2012 81
Dart NeuroScience LLC, H2 2012 82
Omeros Corporation, H2 2012 83
Adeona Pharmaceuticals, Inc., H2 2012 84
Intra-Cellular Therapies, Inc., H2 2012 85
Sparsha Pharma International Pvt. Ltd., H2 2012 86
Tautatis Incorporated, H2 2012 87
Galenea Corp., H2 2012 88
Stelic Institute & Co., H2 2012 89
Cenomed, Inc., H2 2012 90
Gaia BioPharma Limited, H2 2012 91
Heptares Therapeutics Ltd., H2 2012 92
Envoy Therapeutics, Inc., H2 2012 93
BIOPROJET SCR, H2 2012 94
Naurex, Inc., H2 2012 95
Assessment by Monotherapy Products, H2 2012 96
Assessment by Stage and Route of Administration, H2 2012 98
Assessment by Stage and Molecule Type, H2 2012 100
Cognitive Disorders Therapeutics – Drug Profile Updates 248
Cognitive Disorders Therapeutics – Discontinued Products 269
Cognitive Disorders Therapeutics – Discontinued Products (Contd..1) 270
Cognitive Disorders Therapeutics – Dormant Products 271
Cognitive Disorders Therapeutics – Dormant Products (Contd..1) 272
Cognitive Disorders Therapeutics – Dormant Products (Contd..2) 273
Cognitive Disorders Therapeutics – Dormant Products (Contd..3) 274
Cognitive Disorders Therapeutics – Dormant Products (Contd..4) 275
Cognitive Disorders Therapeutics – Dormant Products (Contd..5) 276
Cognitive Disorders Therapeutics – Dormant Products (Contd..6) 277

List of Figures
Number of Products under Development for Cognitive Disorders, H2 2012 21
Products under Development for Cognitive Disorders – Comparative Analysis, H2 2012 22
Products under Development by Companies, H2 2012 23
Products under Investigation by Universities/Institutes, H2 2012 29
Late Stage Products, H2 2012 33
Mid Clinical Stage Products, H2 2012 34
Early Clinical Stage Products, H2 2012 35
Discovery and Pre-Clinical Stage Products, H2 2012 36
Assessment by Monotherapy Products, H2 2012 96
Assessment by Route of Administration, H2 2012 97
Assessment by Stage and Route of Administration, H2 2012 98
Assessment by Molecule Type, H2 2012 99
Assessment by Stage and Molecule Type, H2 2012 100

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos